Open AccessCD137, an attractive candidate for the immunotherapy of lung cancer
Author(s) -
Ye Lingyun,
Jia Keyi,
Wang Lei,
Li Wei,
Chen Bin,
Liu Yu,
Wang Hao,
Zhao Sha,
He Yayi,
Zhou Caicun
Publication year - 2020
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.14354
Subject(s) - cd137 , immunotherapy , lung cancer , immune system , cancer research , cancer immunotherapy , medicine , cancer , targeted therapy , immunology , oncology
Abstract Immunotherapy has become a hotspot in cancer therapy in recent years. Several immune checkpoints inhibitors have been used to treat lung cancer. CD137 is a kind of costimulatory molecule that mediates T cell activation, which regulates the activity of immune cells in a variety of physiological and pathological processes. Targeting CD137 or its ligand (CD137L) has been studied, aiming to enhance anticancer immune responses. Accumulating studies show that anti‐CD137 mAbs alone or combined with other drugs have bright antitumor prospects. In the following, we reviewed the biology of CD137, the antitumor effects of anti‐CD137 Ab monotherapy and the combined therapy in lung cancer.